Save 25% with code AUTUMN25 at checkout.

Join the Defiants

Sign up to be the first to know about special offers and exciting Signos news.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
September 17, 2026
|
Glucose
|
3 min read
|
Written By
Signos Staff

What Is Type 3 Diabetes? The Link Between Alzheimer's and Insulin Resistance

Alzheimer's disease may begin long before someone forgets a name, misses an appointment, or struggles to find the right word.

Years before noticeable symptoms appear, researchers can sometimes detect early changes in how the brain uses glucose, its primary source of energy. When insulin signaling becomes impaired, the brain may lose its ability to take up and use glucose efficiently, leaving certain regions running on less fuel than they need. PET (brain heat map) studies have shown this kind of metabolic decline can occur decades before any cognitive symptoms appear, suggesting that the health of your metabolism may matter for your brain far earlier than most people realize.1

Some researchers have given this connection a name: Type 3 Diabetes. It isn't a formal medical diagnosis, but it reflects a growing body of research linking impaired brain insulin signaling and reduced glucose metabolism to Alzheimer's disease.

What Is Type 3 Diabetes?

Type 3 Diabetes is not an officially recognized type of diabetes. It's a research term, first proposed by researchers Suzanne de la Monte and colleagues to describe the idea that Alzheimer's disease may involve brain insulin resistance, impaired glucose metabolism, and a reduced ability of neurons (brain cells) to use glucose efficiently.2

Researchers don't believe Alzheimer's is simply diabetes occurring in the brain. Insulin resistance is proposed as one contributing factor among many, alongside amyloid-beta accumulation (a buildup of protein fragments between brain cells that interfere with how they communicate), tau tangles (a structural protein that normally keeps brain cells healthy, but in Alzheimer’s, it twists into tangled clumps), genetics, aging, chronic inflammation, and vascular health. Type 3 Diabetes is one lens for understanding part of how Alzheimer's may develop, not the whole picture.

Why Do Some Researchers Call Alzheimer's "Type 3 Diabetes"?

Most people think insulin's only job is managing blood sugar. But insulin plays a broader role inside the brain every day.

In the brain, insulin helps support glucose utilization, memory formation, communication between neurons, brain plasticity (the brain's ability to adapt and form new connections), and neuronal survival.2 When insulin signaling becomes impaired, brain cells may become less efficient at using glucose for energy and communicating with neighboring neurons.

Researchers describe this as a slow energy shortage. Imagine trying to power an entire city while gradually reducing its electricity supply. The buildings remain. The roads remain. But less energy is available to keep everything functioning normally. Something similar may occur when neurons struggle to use glucose efficiently, and over time, that energy deficit may contribute to the cognitive changes associated with Alzheimer's.

How Does Insulin Resistance Affect the Brain?

The brain represents only about 2% of body weight but consumes roughly 20% of the body's total energy.1 The brain contains many different cell types, but neurons, the cells responsible for transmitting signals and driving thought, memory, and movement, have exceptionally high energy demands and rely heavily on glucose to meet them.

When insulin signaling breaks down, the downstream effects can include reduced cellular energy production, oxidative stress (a buildup of harmful molecules that damage cells), mitochondrial dysfunction (the mitochondria are the energy-producing structures inside cells), chronic neuroinflammation, and less efficient communication between neurons.3

Emerging research also suggests that brain insulin resistance may interact with amyloid-beta accumulation, tau phosphorylation (an abnormal process that leads to the tau tangles seen in Alzheimer's brains), and vascular dysfunction (ie, the blood vessels supplying the brain aren’t working as well as they should). Research in Alzheimer's disease has identified abnormalities in brain insulin signaling, including evidence of insulin resistance, backing up the idea that metabolic dysfunction plays a role in the disease.3 These biological processes don't appear to act independently. They appear to influence one another, which is part of why Alzheimer's has been so difficult to treat by targeting any single mechanism alone.

What Does Research Show About Type 3 Diabetes and Alzheimer's?

The evidence connecting metabolism and Alzheimer's has been building for decades.

Epidemiological research has indicated that, in addition to several other metabolic factors, having type 2 diabetes is a risk factor for Alzheimer's disease.4 Brain imaging studies have detected reduced glucose metabolism in people who later develop Alzheimer's, sometimes years before symptoms appear.1 Post-mortem studies of Alzheimer's brains have found evidence of impaired insulin signaling.2 Early clinical research is beginning to investigate whether therapies targeting brain insulin signaling might influence cognitive outcomes.

What researchers still don't know: whether insulin resistance is a cause of Alzheimer's, a consequence of the disease process, both, or one thread in a larger biological network. The research is compelling, but the full picture is still being written.

Can Better Metabolic Health Support Brain Health?

Many of the same habits associated with better metabolic health are also associated with healthier brain aging.

Regular physical activity improves insulin sensitivity and supports cerebral blood flow. Mediterranean and MIND (Mediterranean Intervention for Neurodegenerative Delay) dietary patterns are consistently associated with lower dementia risk. A meta-analysis of 23 studies found that adherence to the Mediterranean diet was associated with a 30% lower risk of Alzheimer's disease specifically.5 Managing blood pressure and blood sugar reduces vascular stress on the brain. Sleep supports both insulin sensitivity and the brain's glymphatic system (its overnight cleansing process, which removes metabolic byproducts including amyloid). Social engagement and lifelong learning appear to strengthen cognitive resilience.

Supporting metabolic health doesn't guarantee protection from Alzheimer's. But metabolic health appears to be one of the modifiable contributors to long-term brain health, which means everyday decisions genuinely matter.

How to Support Brain Health and Metabolic Health

  1. Prioritize both resistance and aerobic exercise. Resistance training builds muscle, one of the body's primary sites for glucose disposal. Aerobic exercise improves insulin sensitivity through different pathways and supports cerebral blood flow directly. Diet and exercise interventions consistently target inflammation, oxidation (ie, the buildup of unstable molecules that cause cellular damage), glucose metabolism, and insulin sensitivity, all factors associated with Alzheimer's risk.⁶ 
  1. Build meals that support steadier glucose responses. Meals built around protein, fiber, healthy fats, and low glycemic carbohydrates (eg, sweet potato, quinoa, barley, chickpeas, beans) allow glucose to enter the bloodstream more gradually, reducing the metabolic stress that large, frequent glucose spikes may contribute to over time.
  1. Protect your sleep. Sleep deprivation temporarily reduces insulin sensitivity and impairs the brain's glymphatic system. A 2026 randomized crossover trial published in Nature Communications provided the first causal human evidence that the glymphatic system actively clears amyloid-beta and tau from the brain during normal sleep, with sleep deprivation significantly reducing that clearance.⁷ Poor sleep means those proteins don't get cleared, and over time they accumulate.
  1. Keep challenging your brain. Learning new skills, reading, novel experiences, and social interaction appear to strengthen cognitive resilience. The brain, like muscle, responds to being challenged.
  1. Support cardiovascular health. The same vessels that carry blood to your heart carry blood to your brain. The 2024 Lancet Commission on dementia prevention identified high LDL cholesterol and high blood pressure as two of the most significant modifiable risk factors for dementia.8 Practically, this means managing blood pressure through regular movement and a diet low in processed foods and sodium, keeping cholesterol in a healthy range, not smoking, and maintaining a healthy weight. 

Why Type 3 Diabetes Is Changing the Way Researchers Think About Alzheimer's

For decades, Alzheimer's research focused primarily on amyloid plaques, tau tangles, and genetics. Those remain critically important. But researchers increasingly recognize that metabolism, inflammation, vascular health, and cellular energy production may all help explain why Alzheimer's develops differently across individuals.

The emerging picture isn't one disease with one single cause. It's a network of interconnected biological systems, and metabolic health appears to be part of that network. Whether or not the term "Type 3 Diabetes" ultimately remains in the scientific vocabulary, it has already shifted one important conversation: brain health and metabolic health appear to be far more interconnected than researchers once believed. The habits that support one may quietly be supporting the other too.

This article is for general informational purposes and is not a substitute for personalized medical advice. If you have concerns about your metabolic or cognitive health, speak with your healthcare provider.

Topics discussed in this article:

References

  1. Mosconi, L. (2013). Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. Clinical and Translational Imaging, 1(4), 217–233. https://doi.org/10.1007/s40336-013-0026-y
  2. de la Monte, S. M., & Wands, J. R. (2008). Alzheimer's disease is type 3 diabetes: evidence reviewed. Journal of Diabetes Science and Technology, 2(6), 1101–1113. https://doi.org/10.1177/193229680800200619
  3. Peng, Y., Yao, S.-Y., Chen, Q., et al. (2024). True or false? Alzheimer's disease is type 3 diabetes: Evidences from bench to bedside. Ageing Research Reviews, 99, 102383. https://doi.org/10.1016/j.arr.2024.102383
  4. Athanasaki, A., Melanis, K., Tsantzali, I., et al. (2022). Type 2 diabetes mellitus as a risk factor for Alzheimer's disease: review and meta-analysis. Biomedicines, 10(4), 778. https://doi.org/10.3390/biomedicines10040778
  5. Fekete, M., Varga, P., Ungvari, Z., et al. (2025). The role of the Mediterranean diet in reducing the risk of cognitive impairment, dementia, and Alzheimer's disease: A meta-analysis. GeroScience, 47(3), 3111–3130. https://doi.org/10.1007/s11357-024-01488-3
  6. Key, M. N., & Szabo-Reed, A. N. (2023). Impact of diet and exercise interventions on cognition and brain health in older adults: A narrative review. Nutrients, 15(11), 2495. https://doi.org/10.3390/nu15112495
  7. Dagum, P., Elbert, D. L., Giovangrandi, L., et al. (2026). The glymphatic system clears amyloid beta and tau from brain to plasma in humans. Nature Communications, 17, 715. https://doi.org/10.1038/s41467-026-68374-8
  8. Livingston, G., Huntley, J., Liu, K. Y., et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572–628. https://doi.org/10.1016/S0140-6736(24)01296-0

Signos Staff

Signos Staff

The Signos team is made up of a medical doctor, certified health coaches, a data scientist, and experienced health, science, and wellness writers.

Table Of Contents
Hands chopping zucchini and tomatoes on a colorful cutting board

Your body runs on glucose. Harness it with Signos.

As seen in:

SIGNOS INDICATIONS: The Signos Glucose Monitoring System is an over-the-counter (OTC) mobile device application that receives data from an integrated Continuous Glucose Monitor (iCGM) sensor and is intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Signos Glucose Monitoring System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Signos Glucose Monitoring System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursions. This information may be useful in helping users to maintain a healthy weight.
The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.
See user guide for important warnings and precautions.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency.

STELO INDICATIONS FOR USE: The Stelo Glucose Biosensor System is an over-the-counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Stelo Glucose Biosensor System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Stelo Glucose Biosensor System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.

OPENLOOP CLINICAL AND PHARMACEUTICAL SERVICES:

Signos is a technology platform and wellness program provider. With the exception of registered dieticians, Signos does not employ licensed health care professionals to practice medicine, does not diagnose, treat, cure, or prevent any disease or medical condition, and does not provide medical advice. You should always consult your own health care professional for diagnosis, treatment, and care regarding any medical condition or health concern. Clinical services accessible through the Signos platform are provided solely by OpenLoop Health and other independent networks of U.S.-licensed clinicians, who exercise their own independent medical judgment to determine eligibility for GLP‑1 treatment based on medical history and assessment responses. These independent providers retain full discretion to prescribe or decline compounded GLP‑1 medications. Signos does not direct, control, or influence any clinical decision made by these providers, and no provider-patient relationship is created between you and Signos.

Compounded medications that may be made available in connection with the Signos program are produced in FDA-registered facilities, but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. Signos does not manufacture, compound, dispense, or distribute any medications. Signos partners with certified U.S. pharmacies to help facilitate access to these medications, but Signos makes no representations or warranties regarding the safety, efficacy, suitability, or quality of any compounded medication. Product appearance may differ from website images.

Medication costs are included in the Signos program; however, inclusion of medication costs does not constitute the practice of medicine or pharmacy by Signos. Results may vary and depend on individual adherence, independent provider guidance, and lifestyle changes. Unless otherwise noted, results referenced reflect individual Signos patient experiences rather than public clinical studies, and no particular outcome is guaranteed.

Nothing on this website or within the Signos platform should be construed as medical advice, a medical diagnosis, or a recommendation for any specific treatment. If you are experiencing a medical emergency, call 911 or your local emergency services immediately.